A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
OSE IMMUNOTHERAPEUTICS operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 75M | 75M | - | 31M | 12M |
| Net Income | 40M | 40M | -25M | -20M | -19M |
| EPS | $1.58 | $1.58 | $-1.28 | $-1.10 | $-1.22 |
| Free Cash Flow | 52M | 52M | -21M | -12M | -22M |
| ROIC | 87.4% | 48.1% | -35.5% | -26.5% | -29.3% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.67 | 1.82 | 0.68 | 0.27 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | 47M | 47M | -25M | -20M | -22M |
| Operating Margin | 62.6% | 62.6% | - | -63.2% | -182.3% |
| ROE | 58.7% | 86.2% | -61.3% | -31.3% | -27.0% |
| Shares Outstanding | 22M | 22M | 19M | 18M | 16M |
| Metric | 2020 | 2021 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 12M | 31M | N/A | 75M | 75M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | -26M | -36M | -19M | -33M | -33M |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -22M | -20M | -25M | 47M | 47M |
| Op. Margin | -182.3% | -63.2% | N/A | 62.6% | 62.6% |
| Net Income | -19M | -20M | -25M | 40M | 40M |
| Net Margin | -158.9% | -64.1% | N/A | 53.6% | 53.6% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -29.3% | -26.5% | -35.5% | 48.1% | 87.4% |
| ROE | -27.0% | -31.3% | -61.3% | 86.2% | 58.7% |
| ROA | -17.1% | -17.2% | -23.9% | 36.3% | 30.2% |
| Cash Flow | |||||
| Op. Cash Flow | -22M | -12M | -21M | 52M | 52M |
| Free Cash Flow | -22M | -12M | -21M | 52M | 52M |
| Owner Earnings | -25M | -18M | -23M | 50M | 50M |
| CapEx | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 314K | 2.3M | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | 0 |
| D&A | 314K | 2.3M | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 2.1M | 3.5M | 1.9M | 2.3M | 2.3M |
| Debt Repayment | 373K | 47K | 3.0M | 5.9M | 5.9M |
| Balance Sheet | |||||
| Net Debt | -15M | -1.4M | 25M | 28M | -18M |
| Cash & Equiv. | 34M | 40M | 20M | 18M | 18M |
| Long-Term Debt | 19M | 36M | 39M | 39M | 39M |
| Debt/Equity | 0.27 | 0.68 | 1.82 | 0.67 | 0.00 |
| Interest Coverage | -65.9 | -19.4 | -9.5 | 7.8 | 7.8 |
| Equity | 70M | 57M | 25M | 69M | 69M |
| Total Assets | 111M | 120M | 89M | 134M | 134M |
| Total Liabilities | 41M | 64M | 64M | 65M | 65M |
| Intangibles | 60M | 60M | 50M | 48M | 48M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 30M | 32M | 13M | 54M | 54M |
| Current Assets | 46M | 52M | 33M | 76M | 76M |
| Current Liabilities | 16M | 20M | 20M | 22M | 22M |
| Per Share Data | |||||
| EPS | -1.22 | -1.10 | -1.28 | 1.58 | 1.58 |
| Owner EPS | -1.59 | -0.97 | -1.20 | 2.29 | 2.29 |
| Book Value | 4.51 | 3.12 | 1.28 | 3.15 | 3.15 |
| Cash Flow/Share | -1.44 | -0.65 | -1.10 | 2.39 | 1.85 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 15.6M | 18.1M | 19.5M | 21.9M | 21.9M |
| Valuation | |||||
| P/E Ratio | -7.5 | -10.3 | -3.7 | 4.8 | 2.0 |
| P/FCF | N/A | N/A | N/A | 3.2 | 1.3 |
| EV/EBIT | N/A | N/A | N/A | 4.1 | 1.1 |
| Price/Book | 2.0 | 3.6 | 3.7 | 2.4 | 1.0 |
| Price/Sales | 11.9 | 6.6 | N/A | 2.2 | 0.9 |
| FCF Yield | -15.8% | -5.7% | -23.3% | 31.6% | 76.7% |
| Market Cap | 142M | 204M | 92M | 166M | 68M |
| Avg. Price | 6.57 | 12.51 | 4.80 | 7.27 | 3.12 |
| Year-End Price | 9.10 | 11.27 | 4.73 | 7.57 | 3.12 |
OSE IMMUNOTHERAPEUTICS passes 3 of 9 quality checks, indicating weak fundamentals.
OSE IMMUNOTHERAPEUTICS trades at 2.0x trailing earnings, compared to its 15-year median P/E of 4.8x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 1.3x vs a median of 3.2x. At current prices, the estimated annualized return to fair value is +66.9%.
OSE IMMUNOTHERAPEUTICS (OSE-PA) has a current P/E ratio of 2.0, compared to its historical median P/E of 4.8. The stock is currently considered Cheap based on its historical valuation range.
OSE IMMUNOTHERAPEUTICS (OSE-PA) has a 5-year average return on invested capital (ROIC) of -10.8%. This is below average and may indicate limited pricing power.
OSE IMMUNOTHERAPEUTICS (OSE-PA) has a market capitalization of $68M. It is classified as a small-cap stock.
OSE IMMUNOTHERAPEUTICS (OSE-PA) does not currently pay a regular dividend.
Based on historical P/E analysis, OSE IMMUNOTHERAPEUTICS (OSE-PA) appears cheap. The current P/E of 2.0 is 59% below its historical median of 4.8. The estimated fair value CAGR (P/E method) is 66.0%.
OSE IMMUNOTHERAPEUTICS (OSE-PA) operates in the Biotechnology industry, within the Healthcare sector.
OSE IMMUNOTHERAPEUTICS (OSE-PA) reported annual revenue of $75 million in its most recent fiscal year, based on SEC EDGAR filings.
OSE IMMUNOTHERAPEUTICS (OSE-PA) has a net profit margin of 53.6%. This is a strong margin indicating high profitability.
OSE IMMUNOTHERAPEUTICS (OSE-PA) generated $52 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
OSE IMMUNOTHERAPEUTICS (OSE-PA) has a debt-to-equity ratio of 0.67. This indicates moderate leverage.
OSE IMMUNOTHERAPEUTICS (OSE-PA) reported earnings per share (EPS) of $1.58 in its most recent fiscal year.
OSE IMMUNOTHERAPEUTICS (OSE-PA) has a return on equity (ROE) of 86.2%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 4 years of financial data for OSE IMMUNOTHERAPEUTICS (OSE-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
OSE IMMUNOTHERAPEUTICS (OSE-PA) has a book value per share of $3.15, based on its most recent annual SEC filing.